Wells Fargo raised the firm’s price target on AptarGroup (ATR) to $170 from $162 and keeps an Overweight rating on the shares. The firm notes the company posted a high-quality Q1 earnings beat with its largest profit contributor showing year-over-year growth and margin improvement on a tough comp despite the macro challenges. Wells continues to view AptarGroup as a solid compounder.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ATR:
- AptarGroup’s Strong Pharmaceutical Growth and Strategic Initiatives Drive Buy Rating
- AptarGroup’s Q1 2025 Results: Sales Dip, Pharma Grows
- AptarGroup’s Earnings Call: Growth Amid Challenges
- AptarGroup’s Mixed Segment Performance and Economic Pressures Lead to Hold Rating
- AptarGroup reports Q1 adjusted EPS $1.20, consensus $1.15